Literature DB >> 1349752

Changes in dopamine D1, D2 and D3 receptor mRNA levels in rat brain following antipsychotic treatment.

P R Buckland1, M C O'Donovan, P McGuffin.   

Abstract

The effects of administration of antipsychotic drugs (1-32 days, twice per day) on the rat brain mRNA levels of dopamine D1, D2 and D3 receptors has been assessed by a novel procedure utilising solution hybridisation with oligonucleotides. Saline and sulpiride (10 mg/kg/injection) had no effect on D1, D2 and D3 receptor mRNA levels. Haloperidol (1.5 mg/kg/injection) elicited increases in D1, D2 and D3 receptor mRNA levels of 100%, 100% and 300% respectively, after 32 days and loxapine (2 mg/kg/injection) elicited increases of 450%, 150% and 550%, respectively. These results indicate that the up-regulation of dopamine receptors may be associated with the occurrence of tardive dyskinesia but not the clinical mode of action of antipsychotics.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349752     DOI: 10.1007/bf02244818

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  18 in total

1.  Simultaneous quantification of several mRNA species by solution hybridisation with oligonucleotides.

Authors:  M C O'Donovan; P R Buckland; P McGuffin
Journal:  Nucleic Acids Res       Date:  1991-06-25       Impact factor: 16.971

2.  Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.

Authors:  R K Sunahara; H C Guan; B F O'Dowd; P Seeman; L G Laurier; G Ng; S R George; J Torchia; H H Van Tol; H B Niznik
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

3.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.

Authors:  P Sokoloff; B Giros; M P Martres; M L Bouthenet; J C Schwartz
Journal:  Nature       Date:  1990-09-13       Impact factor: 49.962

4.  Cloning and expression of human and rat D1 dopamine receptors.

Authors:  Q Y Zhou; D K Grandy; L Thambi; J A Kushner; H H Van Tol; R Cone; D Pribnow; J Salon; J R Bunzow; O Civelli
Journal:  Nature       Date:  1990-09-06       Impact factor: 49.962

5.  Alternative splicing directs the expression of two D2 dopamine receptor isoforms.

Authors:  B Giros; P Sokoloff; M P Martres; J F Riou; L J Emorine; J C Schwartz
Journal:  Nature       Date:  1989 Dec 21-28       Impact factor: 49.962

Review 6.  Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs.

Authors:  R J Baldessarini; D Tarsy
Journal:  Annu Rev Neurosci       Date:  1980       Impact factor: 12.449

7.  Cloning and expression of a rat D2 dopamine receptor cDNA.

Authors:  J R Bunzow; H H Van Tol; D K Grandy; P Albert; J Salon; M Christie; C A Machida; K A Neve; O Civelli
Journal:  Nature       Date:  1988 Dec 22-29       Impact factor: 49.962

8.  Clinical implications of receptor sensitivity modification.

Authors:  A J Friedhoff; J C Miller
Journal:  Annu Rev Neurosci       Date:  1983       Impact factor: 12.449

9.  Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics.

Authors:  D G Owens; E C Johnstone; C D Frith
Journal:  Arch Gen Psychiatry       Date:  1982-04

10.  Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.

Authors:  H H Van Tol; J R Bunzow; H C Guan; R K Sunahara; P Seeman; H B Niznik; O Civelli
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

View more
  11 in total

Review 1.  The role of candidate genes in the etiology of schizophrenia.

Authors:  K C Murphy; P McGuffin
Journal:  Mol Med       Date:  1996-11       Impact factor: 6.354

2.  Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.

Authors:  B Glenthøj
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

3.  Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Authors:  Amarendra N Singh; Cia Barlas; Huma Saeedi; Ram K Mishra
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

4.  A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons.

Authors:  D Lévesque; M P Martres; J Diaz; N Griffon; C H Lammers; P Sokoloff; J C Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine.

Authors:  H Y Meltzer; M A Lee; R Ranjan; E A Mason; P A Cola
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

6.  Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA levels in rat brain following antipsychotic treatment.

Authors:  P R Buckland; M C O'Donovan; P McGuffin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 7.  Does the difference between physically active and couch potato lie in the dopamine system?

Authors:  Amy M Knab; J Timothy Lightfoot
Journal:  Int J Biol Sci       Date:  2010-03-09       Impact factor: 6.580

8.  Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effects of dopamine receptor agonists and antagonists.

Authors:  M Y Zhu; A V Juorio; I A Paterson; A A Boulton
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

9.  The neuroprotective disease-modifying potential of psychotropics in Parkinson's disease.

Authors:  Edward C Lauterbach; Leonardo F Fontenelle; Antonio L Teixeira
Journal:  Parkinsons Dis       Date:  2011-12-27

10.  Risperidone Induced DNA Methylation Changes in Dopamine Receptor and Stathmin Genes in Mice Exposed to Social Defeat Stress.

Authors:  Fatima Zahra Rami; Thong Ba Nguyen; Young-Eun Oh; Maryam Karamikheirabad; Thi-Hung Le; Young-Chul Chung
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-05-31       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.